Skip to main content
Name tag

Sam North

Education

Royal Australian Navy - 👉 Bachelor of Electronic and Communications Engineering

Written For

Releaf, Business Of Cannabis, CPD, Cannabis Now Magazine, High Times, Cookies Seeds, Fast Buds, MSNL, Paradise Seeds, Premium Cultivars

Sam North is a content writer at Releaf, specialising in medical cannabis, digital health, and patient education within a UK regulatory framework. After a decade immersed in the cultivation side of the cannabis industry, Sam moved into digital in 2020. He worked across the recreational space with seed companies, CBD brands, and cannabis publications, before transitioning into the medical cannabis sector in early 2023 and joining Releaf in April of that year. Today, his work spans both content and SEO, with a focus on how the two support patient understanding and long-term organic growth. He writes and shapes educational content, research breakdowns, and patient-facing web copy, ensuring it is clear, clinically accurate, and aligned with UK compliance requirements. At Releaf, Sam’s focus is on making medical cannabis more understandable and accessible to patients, while maintaining a high standard of accuracy, compliance, and trust.

Releaf articles

Pride, PTSD, and plant-based approaches

Each year in June, LGBTQ+ Pride events take place around the world. These events offer an opportunity to celebrate the LGBTQ+ community, honour their contributions, and recognise the ongoing struggle for equality. But June also marks PTSD Awareness Month and, as these two important events coincide, it is important to recognise the increased rates of PTSD among LGBTQ+ individuals, understand the reasons behind this, and improve awareness of available treatment options.

The ripple effect: medical cannabis: another tool to support patients and carers

This Carers Week, we are thinking about all the people across the UK who help care for someone in need. Proper treatment that delivers the best clinical outcomes is often about far more than a single option, but rather a range of choices that fit the patient. For an increasing number of patients in the UK, medical cannabis is another tool that helps, and when it does, the people supporting them can feel the difference too. We surveyed 1,669 Releaf patients, and their answers point to a benefit that reaches beyond the patient alone.

Decoding Cannabis: Over the limit, but not impaired? What the science shows

The UK (and many other countries) sets its drug-driving THC limit at 2 µg/L of blood, but is that a measure of impairment, or just detection? A 2026 simulator study found frequent cannabis users were no more impaired than non-users 12 to 15 hours after smoking, despite still exceeding that threshold. We decode what the research really shows, and why it is relevant for medical cannabis patients who are worried about getting behind the wheel.